Click here to learn more
Stansberry Research

Dear Reader,

Write this down: "CRISPR."

Soon, you'll hear this word everywhere… and if you know what to do, it could make you rich.

It's a new breakthrough where a small early stake could easily multiply into tens of thousands of dollars.

Stansberry Research has a 19-year history of finding these massive investment opportunities for everyday Americans.

For example, we gave readers the chance to make 592% on a laser company called JDS Uniphase… 995% on a gold mining stock… and 708% using a little-known type of investment called a "warrant."

But the opportunity I want to tell you about today is much, much bigger…

It's a breakthrough mankind has waited centuries for… and it's about to explode onto the mainstream.

Soon, you'll hear it every time you turn on the news… log on to Facebook… or meet with friends.

Experts are calling it the "Discovery of the Century"…

And I think most Americans will be shocked when they hear what it's capable of doing

Congress, DARPA, and the CIA have all requested briefings on it.

And investment analysts predict it's on track to grow 66,000% and become larger than the entire pharmaceutical market.

This single breakthrough could soon be worth nearly TWICE as much as every penny spent on pills for cancer, pain, diabetes, and mental health, combined.

It could kick-start a mania… and for a limited time, you have a chance to get in on the ground floor.

For your first look at "The Discovery of the Century," click here.

Regards,

Brett Aitken
Managing Director, Stansberry Research.

P.S. Mark my words: this opportunity will probably pass most people by, just as buying into Apple or Amazon did back in the late 1990s, or Facebook in 2012… or Bitcoin when it still traded for about a nickel…

It’s the type of thing you'll look back on and think, "Man, I knew that was going to be huge. Why didn't I trust my gut?"

Don't miss out on the next big mania… click here to learn more
Pharmaceutical Sales by Category



All contents of this e-mail are copyright 2018 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.

DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.

To unsubscribe from this mailing, click here: Unsubscribe